Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2017-04-20 / JCI Insight 2017 Apr;2(8)Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2017-04-18 / Oncotarget 2017 Apr;8(16):27252-27262Immune Modulation by Vitamin D: Special Emphasis on Its Role in Prevention and Treatment of Cancer
/in International Publications, Micronutrients /von 2017-04-18 / 2017 May;39(5):884-893Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
/in Dendritic Cells, Glioblastoma, International Publications /von 2017-04-15 / Clin. Cancer Res. 2017 04;23(8):1898-1909Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia
/in Acute Leukemia, Dendritic Cells, International Publications /von 2017-04-14 / Cancer 2017 Aug;123(16):3061-3072Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase II trial
/in Hepatocellular Carcinoma, Hyperthermia, International Publications /von 2017-04-13 / Oncotarget 2017 Aug;8(32):52651-52664Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
/in Brain Tumors in Children, Checkpoint-Inhibitors, Glioblastoma, International Publications /von 2017-04-12 / Onco Targets Ther 2017;10:2097-2106Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2017-04-07 / J Hematol Oncol 2017 04;10(1):82Reirradiation for locally recurrent breast cancer
/in Breast Cancer, Hyperthermia, International Publications /von 2017-04-07 / Breast 2017 Jun;33:159-165
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de